Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q4 FY25 Earnings Presentation
35 slides from Jubilant Ingrevia's earnings presentation, May 2025
Slide 1: Investor Presentation May 2025
Jubilant Ingrevia Limited Investor Presentation M ay 2 02 5 Environment Social Governance O2 contract – Sourcing 35% of total energy through renewables S&P DJSI – Obtained 92 percentile in Global Chemical Industries EcoVadis – Achieved Gold rating with Top 95 percentile
Slide 2: Forward-looking statements and notes
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product
Slide 3: Chairman's message
“We are pleased to announce the sustained growth in revenue and margins for our Specialty Chemicals and Nutrition businesses. Our ongoing cost reduction efforts have further boosted our profitability, with quarter’s EBITDA margin reaching 14.7% and Profit After Tax increasing by 153% on YoY basis. D
Slide 4: Business Update
Business Update: In the Specialty Chemicals Business segment, overall volumes remained stable. We are observing continuous growth momentum across our Pyridine & Picoline, Fine Chemicals and CDMO businesses, with an expanded pipeline of newer opportunities for coming quarters. In certain segments, we
Slide 5: Table of Contents
Table of Contents 0 6 Compa ny Overview 1 3 Growth Roadmap 1 9 Q4’FY25 Highlights 2 6 Business Segments Update 5
Slide 6: Company Overview
Company Overview . Visuals of our New Diketene Derivatives Plant in Gajraula 6
Slide 7: Transformation into Forward Specialty Leader
Transformation into Forward Specialty Leader Expansion & Integration 2023 onwards Origin Diversification 2011 - 2023 1978 – 1990 1990 – 2011 • Expansion of Pyridine • Started as VAM • Forward integration into • Foray into Pyridine derivatives Organics Pyridine derivatives Chemistry • Foray into Dike
Slide 8: Business segments: Specialty Chemicals, Nutrition, Chemical Intermediates
1 2 3 Specialty Nutrition Chemical Chemicals & Health Solutions Intermediates • CDMO • Fine Chemicals • Animal Nutrition and Health Solutions • Acetic Anhydride • Acetaldehyde • Pyridine and Picolines • Human Nutrition Solutions • Ethyl Acetate • Bio Acetic Acid Globally #1 Globally #2 Globally #2 •
Slide 9: Nutrition & Health Solutions revenue mix
Consumer 4% ROW Nutrition 9% North & Health Agro America Solutions 19% Pharma 9% 18% SpecialtyC 32% India hemicals4 53% 4% Europe & Japan Chemical Industrial 29% Intermediates 24% 39% Nutrition 21% 9
Slide 10: 2300+ people, 130+ products, 1500+ customers
Gajraula Bharuch Nira Savli Ambernath Uttar Pradesh, India Gujarat, India Maharashtra, India Gujarat, India Maharashtra, India Integrated facility for CDMO & Fine Chemicals Chemical Intermediates Animal Nutrition Microbial Control Specialty Chemicals & Nutrition and Chemical Facility & Health Soluti
Slide 11: R&D Centers, Scientists, PhDs
R&D Center G. Noida UP, India Pilot Plant at Gajraula UP, India 3 150 26 R&D Centers Scientists PhDs 11
Slide 12: Business Leaders
SS Bhartia HS Bhartia Deepak Jain Chairman Co-Chairman & Whole CEO & MD Time Director 20 yrs exp Business Leaders Function Leaders Specialty Chemicals Nutrition & Health Chemical Intermediates Varun Gupta Vijay Kumar Srivastava Ambrish Dixit Ashish Kr. Sinha Himanshu Dhapola Chief Financial Officer
Slide 13: Growth Roadmap
INGREVIA wW | ati JUBILANT , LA
Slide 14: Purpose, Vision, Values
PURPOSE VISION Enable a Sustainable World through Chemistry Leading provider of innovative solutions in our core chemistries globally World-class, Customer Innovation & People Safe Operations ESG Leader CAPABILITIES/ Centricity Technology Focused CORE PILLARS Inspire Challenge Innovate Excel Collabo
Slide 15: Pinnacle 3.4.5 growth path
We set out on an ambitious growth path — Pinnacle 345 per INGREVIA times sal times iyi year ill REVENUE EBITDA HORIZON
Slide 16: Today vs Tomorrow
Today Past Tomorrow Future Portfolio High dependence on commoditized chemicals Higher focus on Specialty chemicals (downstream value-added products, CDMO) Mindset Primarily product / manufacturing first mindset “Customer-centric” approach R&D focus Focus on incremental innovation of existing product
Slide 17: Pinnacle 3.4.5 Growth Pillars
PINNACLE 3.4.5 G R O W T H P I L L A R S New Growth Areas A Specialty Chemicals B Nutrition & Health solutions C Chemical Intermediates Pyridine & Picoline Retain Global leadership (#1 position, cost leadership) Animal Nutrition Acetic Anhydride Scale up Oilfield chemicals Feed Vit B3: Extend global
Slide 18: Key milestones and achievements
WEF Lighthouse award at Davos 120 Cr+ of Lean/Surge/BE Investor day in initiatives Turnaround in Commissioning of Mumbai (28th Feb) Europe/US/ Japan DIKETENE Derivatives roadshows - 100+ Specialty and Cosmetic Grade Nutrition with Niacinamide plant Ecovadis and DJSI plants customers increase in EBIT
Slide 19: Q4 & FY25 Highlights
ww JUBUANT INGREVIA Q4 & FY25 Highlights 19
Slide 20: Pharma, Agrochem and Nutrition market update
PHARMA • Consistent volume demand across segments, especially in our Fine Chemicals portfolio • Prices remain stable across various segments, with certain areas seeing an increase. • Demand for paracetamol end-use remains subdued as customers run their plants below optimal capacity. AGROCHEM • Globa
Slide 21: Core product platforms continue to drive growth
• Pyridine & Picoline: Globally #1 position in P&P (only scaled non-Chinese player), Significant volume Core product platforms continue to growth in FY25; Prices moved up in select segments drive growth and leadership; Acetyls • Niacinamide: Maintained leadership position (Top 2) in feed grade with
Slide 22: Q4 FY25 financial summary
Particulars1 Q4'FY24 Q3'FY25 Q4'FY25 Q-o-Q Y-o-Y FY24 FY25 Y-o-Y Total Revenue 1,074 1,057 1,051 -1% -2% 4,136 4,178 1% Total EBITDA 101 148 155 5% 54% 456 557 22% EBITDA Margin (%) 9% 14% 15% 11% 13% Profit After Tax 29 69 74 7% 153% 183 251 37% Profit After Tax Margin (%) 3% 7% 7% 4% 6% Basic and
Slide 23: Quarterly EBITDA and margins trend
Despite the pressure on acetyl business, we continue to see strong EBITDA growth EBITDA (INR Crs.) EBITDA Margins 155 148 Highest EBITDA 135 Margin in last 12 125 126 quarters 119 14.7% 14.0% 104 101 12.9% 12.1% 11.6% 11.6% 10.8% 9.4% Q1FY24 Q2FY24 Q3FY24 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Revenue 1
Slide 24: Segment-wise EBITDA Share (%)
Segment-wise EBITDA Share (%) 6% 13% 25% 27% 17% 36% 36% 43% 40% 15% 48% 46% 45% 49% 16% 16% 7% 14% 5% 14% 8% 4% 13% 12% 76% 72% 56% 59% 57% 52% 50% 46% 47% 46% 40% 43% Specialty Chemicals Nutrition & Health Chemical Intermediates 24
Slide 25: Segment EBITDA: Specialty Chemicals and Nutrition
Specialty Chemicals Nutrition & Health Solutions EBITDA (Rs Cr.) EBITDA (Rs Cr.) Y.o.Y Growth 93% Y.o.Y Growth 237% Q.o.Q Growth 7% Q.o.Q Growth 17% 129 121 29 25 67 9 14% 26% 27% 5% 13% 16% Q4 FY24 Q3 FY25 Q4 FY25 Q4 FY24 Q3 FY25 Q4 FY25 Notable increase in the volumes and prices in Pyridine QoQ an
Slide 26: Business Segments Overview
Business Segments Overview 26
Slide 27: Specialty Chemicals segment
1 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Steady demand growth from the end-use segment maintained strong volumes, while Particulars1 Q4'FY24 Q3'FY25 Q4'FY25 Q-o-Q Y-o-Y FY24 FY25 Y-o-Y prices remained stable with increases in Segment Revenue 475 468 487 4% 2% 1,585.5 1,818 15% certain segments % Sha
Slide 28: Nutrition & Health Solutions segment
2 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS 1 Particulars Q4'FY24 Q3'FY25 Q4'FY25 Q-o-Q Y-o-Y FY24 FY25 Y-o-Y Increased sales volume on YoY basis. Segment Revenue 165 190 190 0% 15% 680 747 10% Niacinamide pricing improved on YoY basis % Share of Overall Revenue 15% 18% 18% 16% 18% EBITDA 9 25 29 17% 2
Slide 29: Chemical Intermediates segment
3 MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Acetic Anhydride is still encountering challenges from its main end-use markets, e.g. Paracetamol Particulars1 Q4'FY24 Q3'FY25 Q4'FY25 Q-o-Q Y-o-Y FY24 FY25 Y-o-Y Greater emphasis on Ethyl Acetate volumes Segment Revenue 435 400 375 -6% -14% 1,870 1,612 -14%
Slide 30: Annexures
J, ww Ieneva IT lA
Slide 31: Consolidated profit and loss statement
1 Particulars Q4'FY24 Q3'FY25 Q4'FY25 QoQ YoY FY24 FY25 YoY Revenue from operations a) Sales/Income from operations 1060 1046 1038 -1% -2% 4100 4124 1% b) Other operating income 14 11 13 22% -8% 35 54 53% Total revenue from operations 1074 1057 1051 -1% -2% 4136 4178 1% Other income 10 9 8 -11% -12%
Slide 32: Segment revenue, EBITDA and margins
Particulars1 Q4'FY24 Q3'FY25 Q4'FY25 QoQ (%) YoY (%) FY24 FY25 YoY (%) Revenue Speciality Chemicals 475 468 487 4% 2% 1,586 1,818 15% Nutrition & Health Solutions 165 190 190 0% 15% 680 747 10% Chemical Intermediates 435 400 375 (6%) (14%) 1,870 1,612 (14%) Total Revenue from Operations 1,074 1,057
Slide 33: Debt and working capital
Particulars1 31-Mar-24 31-Dec-24 31-Mar-25 Long Term Borrowings 450 457 396 Short Term Borrowings 283 291 360 Total Gross Debt 733 748 756 Cash & Equivalent 80 67 98 Total Net Debt 653 681 658 YoY change 1% The capex for the quarter was Rs 65 Crore and YTD was Rs 365 Crore, which was primarily funde
Slide 34: Earnings conference call details
Diamond Pass Log-In Date : May 13th, 2025 Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, passcode and a pin for the concall on the re
Slide 35: Thank you for your time
Jubilant Ingrevia Limited is a globally integrated Life Sciences & For Investors: Specialty Chemicals company, serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It has a broad Pavleen Taneja portfolio of over 130+ products and customized solutions that are Jubilant